2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1075

Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with Systemic Lupus Erythematosus on Immunosuppressive Drugs
Abstract Number: 57

Risk of Hospitalized Infection in a Psoriasis/Psoriatic Arthritis Cohort
Abstract Number: 2665

Risk of Hydrocephalus and/or Macrocephaly in Children Born to Mothers with SLE
Abstract Number: 1910

Risk of Hypersensitiviy Among Medicare Patients with Rheumatoid Arthritis Who Were Taking Biologics
Abstract Number: 518

Risk of Infection Associated with Subsequent Biologic Use Following Rituximab—Results from a National RA Patient Registry
Abstract Number: 1082

Risk of Intra Cranial Hemorrhage among Patients with Anti-Phospho-Lipid-Antibody (aPL) syndrome vs Systemic Lupus Erythematosus (SLE) in Stroke Population: A Nationwide Analysis
Abstract Number: 726

Risk of Ischemic Stroke in Patients with Systemic Sclerosis: A Systematic Review and Meta-Analysis
Abstract Number: 1849

Risk of Malignancy Among Medicare Psoriasis/Psoriasis Arthritis Patients
Abstract Number: 1546

Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis Arthritis Patients
Abstract Number: 1589

Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort
Abstract Number: 1839

Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis
Abstract Number: 1400

Risk of Venous Thromboembolic Events in Patients with Rheumatoid Arthritis: A Meta-Analysis of Observational Studies
Abstract Number: 2531

Risk of Venous Thromboembolism in Patients with Sjogren’s Syndrome: A Systematic Review and Meta-Analysis
Abstract Number: 1524

Rituximab Done! What’s Next in RA?
Abstract Number: 2804

Rituximab in IgG4-Related Disease: A Large Single-Center Experience

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].